Waldencast plc filings document the company's foreign-issuer reporting for a beauty and wellness platform with Obagi Medical and Milk Makeup as operating brands. Form 6-K reports furnish financial results, interim consolidated financial statements, earnings-date notices, and business updates covering skincare, cosmetics, medical aesthetics, distribution, operating expenses, and brand performance.
The filing record also covers annual general meeting voting, director re-appointments, auditor ratification, credit-facility agreements, trademark transfer and coexistence agreements involving the Obagi mark in Japan, and registration-statement incorporation references. Other disclosures address the completed SEC investigation connected to prior financial restatement matters and material weaknesses in internal control over financial reporting.
Waldencast plc (WALD) filed Form 15 on October 15, 2026, to terminate registration under Section 12(g) of its Class A ordinary shares and redeemable warrants and suspend reporting obligations under Section 15(d) of the Exchange Act. Upon filing, its obligation to file periodic and current SEC reports, including Form 20-F annual reports and Form 6-K current reports, was suspended immediately. Deregistration is expected to become effective 90 days after filing or sooner if the SEC determines a shorter period.
Each whole warrant is exercisable for one Class A ordinary share at $11.50 per share. As of October 5, 2026, Waldencast's Class A ordinary shares and warrants were quoted on the Pink Limited market of OTC Markets Group under MLKMF and MLKWF, respectively.
Waldencast plc (WALD) filed a Form 15 to terminate registration under Section 12(g) for its Class A ordinary shares and redeemable warrants. Each warrant is exercisable for one Class A ordinary share at an exercise price of $11.50 per share.
Waldencast plc completed the sale of its Obagi Medical business to Bridgepoint on July 30, 2026, in a transaction valued at up to $460 million. At closing, it repaid $178.4 million of outstanding indebtedness under the Lumina Credit Agreement in full and received $149.9 million in net cash proceeds after placing $3.0 million in escrow. Obagi results are presented as discontinued operations.
For the six months ended June 30, 2026, continuing-operations revenue was $26.1 million, down 57.1% from $60.9 million; net loss was $94.9 million, up 96.5% from $48.3 million; and Adjusted EBITDA was negative $23.2 million versus $0.02 million. Continuing-operations cash and cash equivalents were $138.6 million as of August 31, 2026. The Board approved voluntary delisting and deregistration of its Class A ordinary shares and warrants from Nasdaq; after delisting, the company intends to seek OTC quotation under MLKM. Waldencast describes a goal to double 2025 revenue over five years and build toward an Adjusted EBITDA margin in the mid-20s once Milk Makeup is back at scale, calling this a North Star rather than financial guidance.
Waldencast plc filed Form 25 on September 24, 2026, to remove its Class A ordinary shares and redeemable warrants from Nasdaq listing and deregister them under Section 12(b) of the Exchange Act. Each whole warrant is exercisable for one Class A ordinary share at $11.50 per share.
The last Nasdaq trading day is expected to be on or about October 2, 2026, and delisting is expected to become effective on or about October 4, 2026. Section 12(b) deregistration is expected to become effective 90 days after the Form 25 filing. Waldencast intends to file Form 15 on or about October 5, 2026; upon filing, its reporting obligations under Sections 12(g) and 15(d) will be suspended immediately. The company reserves the right to withdraw or postpone the filings before they become effective.